As final US drug fails, SciClone focuses on breaking China
This article was originally published in Scrip
Getting out of drug development is not generally a seen a value-creating move, but SciClone Pharmaceuticals turned lemons into lemonade on 2 March when it announced that it would no longer pursue approval by the US FDA of its Phase II oral mucositis drug SCV-07, enabling the company to focus solely on its China business strategy.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.